In a clinical setting, Guardant products powered by the Infinity platform can have:
Even faster turnaround times
post-sample receipt.2
Enhanced sensitivity with
100x to 1000x more signals
available to analyze.1
New insights across the
continuum of care,
from MRD to progression.
The Guardant Infinity platform combines epigenomic and genomic profiling via liquid biopsy to offer a truly multidimensional view of cancer.¹
The next era of precision oncology is here—see what’s next, now with the Guardant Infinity platform.
Home Oncology Portfolio Partnerships European Policy Guardant Infinity™ for BioPharma